



Atty Docket No. 701826-055820

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 09/719,870
Applicant: Masad J. Damha et al.
Filed: April 12, 2001
For: ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β -ARABINOFURANOSE AND ITS ANALOGUES
Group: 1635
Examiner: Janet L. Epps-Ford

Confirmation No.: 5859
Customer No.: 50828

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

1. Transmittal Form (1 pg.);
2. Amendment (10 pp.);
3. Replacement Figure 4 (1 pg.);
4. Return Receipt Postcard;

is on the date shown below being:


MAILING

X deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450


FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

Date: September 2, 2005


Signature

Nicole M. Aguirre
(type or print name of person certifying)



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/719,870
Filing Date	April 12, 2001
First Named Inventor	Masad J. Damha
Art Unit	1635
Examiner Name	Janet L. Epps Ford
Attorney Docket Number	701826-055820

ENCLOSURES (Check all that apply)

- | | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance Communication to TC |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input checked="" type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | Replacement Figure 4; Certificate of Mailing; and Return Receipt Postcard |
| <input type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Reply to Missing Parts/Incomplete Application | <input type="checkbox"/> Landscape Table on CD | |
| <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | | |

Remarks

Confirmation No. 5859
Customer No. 50828

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	NIXON PEABODY LLP		
Signature			
Printed name	David S. Resnick		
Date	9/2/05	Reg. No.	34,235

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Nicole M. Aguirre

Date

9/2/05

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Att. Docket No. 701826-055820

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 09/719,870
Applicant: Masad J. Damha et al.
Filed: April 12, 2001
For: ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β -ARABINOFURANOSE AND ITS ANALOGUES
Group: 1635
Examiner: Janet L. Epps-Ford

Confirmation No.: 5859
Customer No.: 50828

CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

9/2/05
Date

Nicole M. Aguirre
(type or print name of person mailing paper)

Nicole M. Aguirre
(signature of person mailing paper)

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

AMENDMENT

Sir:

This communication is responsive to the Office Action dated June 2, 2005, a response to which is due on or before September 2, 2005. Please amend the above-identified patent application as follows:

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

A Replacement Drawing of Figure 4, pursuant to the Examiner's request for a clearer image, is attached hereto.

Remarks/Arguments begin on page 8 of this paper.